In Medicine
The probability that we'd observe that A beats B more often than we did under the null hypothesis that B beats A.
In Economics
A measure of the chance that observed differences occur purely due to random variation as opposed to a real difference in effects.
Know first
Named as a prerequisite by the lectures that define this. The number is how many say so. A grey one has no page yet.
Opens up
Concepts that name this one as a prerequisite.
Bonferroni procedure1Clinical significance vs. statistical significance1Clinical vs statistical significance1Conditional power1Confidence interval for superiority1False discovery rate adjusted p-value1Family-wise error rate1Fisher's exact test1Hypothesis testing in RCTs1Randomization inference1Secondary exploratory analysis1
In Medicine
2Each in their own terms, from the easiest level.
CEU CMC Vellore
The probability that the observed data are compatible with the null hypothesis.
In Economics
1Lectures that assume it
9- Poverty Traps: Graduation Programs
- SECONDARY ANALYSIS OF A CLINICAL TRIAL _ DR SHRIKANT BANGDIWALA
- Land Markets (Part 1)
- TYPE OF HYPOTHESIS _ DR SHRIKANT BANGDIWALA
- CONDITION POWER IN INTERIM ANALYSES OF A CLINICAL TRIAL _ DR. L. JEYASEELAN
- COMMON RCT DESIGNS IN PHASE IIB AND III CLINICAL TRIALS - PART II _ DR. SHRIKANT I. BANGDIWALA
- Day 1 (I) - Why do we need clinical trials _ Prof. SI Bangdiwala
- Day 2 (IV) - Study efficacy outcomes_ Prof. Shrikant I Bangdiwala
- Day 2 (II) - Design considerations - Necessary sample size_ Prof. L.Jeyaseelan
Connections
22The lectures that define it or assume it, and the concepts next to it.
Concepts10
Lectures12
- Measurement and Timing
- Moving to Opportunity vs. Place-Based Approaches
- TYPES OF ANALYSIS _ DR SHRIKANT BANGDIWALA
- Poverty Traps: Graduation Programs
- SECONDARY ANALYSIS OF A CLINICAL TRIAL _ DR SHRIKANT BANGDIWALA
- Land Markets (Part 1)
Show 6 moreShow fewer
- TYPE OF HYPOTHESIS _ DR SHRIKANT BANGDIWALA
- CONDITION POWER IN INTERIM ANALYSES OF A CLINICAL TRIAL _ DR. L. JEYASEELAN
- COMMON RCT DESIGNS IN PHASE IIB AND III CLINICAL TRIALS - PART II _ DR. SHRIKANT I. BANGDIWALA
- Day 1 (I) - Why do we need clinical trials _ Prof. SI Bangdiwala
- Day 2 (IV) - Study efficacy outcomes_ Prof. Shrikant I Bangdiwala
- Day 2 (II) - Design considerations - Necessary sample size_ Prof. L.Jeyaseelan